Senior Manager, Scientific Communications

Hiring By - Biostaffic

 BioPharma

Redwood City, California - United States

Job Highlights

Not Disclosed

Mid-Senior level

Posted 4 months ago
Job details
The Senior Manager of Scientific Communications will be responsible for the development and execution of publication plans for assigned assets. The position will oversee the execution of scientific publications (ie, clinical manuscripts, abstracts, posters, and oral presentations) that fulfill the strategic publication plan and scientific communications objectives. The role will be a balance of leadership and taking a “hands-on” approach in a lean organization. As such, the Senior Manager of Scientific Communications will be required to perform medical writing functions such as developing outlines, drafts, finalizing, and submitting data disclosures in close collaboration with internal and external stakeholders. They will also be responsible for closely managing consultants and vendors who may be hired to perform these functions. The position reports directly to the Vice President of Medical Affairs, requiring close cross-functional collaboration with internal stakeholders including clinical development, medical affairs, legal, regulatory, and communications. External engagement with key opinion leaders, healthcare providers, vendors, and other pertinent entities will also be an important aspect of this role.
Essential Responsibilities: 
  • Lead development and tactical execution of publication plans (ie, clinical manuscripts, abstracts, posters, and oral presentations), meeting established timelines and budgets
  • Lead cross-functional team(s) for assigned assets, including leading team meetings, driving the execution of publication plans, developing timelines, developing content, and incorporating input from key stakeholders
  • Review all publications to ensure quality and alignment with scientific communication platforms and supporting communications
  • Partner with the Medical Monitors, Chief Medical Officer, and Chief Development Officer to ensure seamless transfer of the scientific publications strategic plan and oversee pull-through to publication plan and supporting tactics
  • Complete the execution of publication projects, within specified timelines, and ensure quality publication deliverables
  • Support the development of educational events and activities in alignment with program goals and objectives
  • Manage external vendors/medical agencies assisting with medical content planning and execution, ensuring deliverables are developed using good practices and cost-effective manner
  • Address and resolve publications-related issues
Education and Experience Requirements:
  • Minimum of bachelor’s degree required; PhD, PharmD, Master’s degree preferred (relevant professional certification/credential [eg, CMPP, AMWA] is a plus)
  • At least 4-5 years of medical/scientific publications (or related) experience required
  • Pharmaceutical industry or related (eg, medical communications agency) experience required
  • Experience in small molecule therapeutics, diabetes and/or metabolic therapeutic areas required, prior launch experience a plus.
  • Demonstrated abilities in a leadership capacity required
  • Ability to understand and interpret medical data required
  • Knowledge of product therapeutic areas preferred; working knowledge of statistical concepts and techniques required
  • Knowledge of clinical/scientific publication structure, content, and quality; knowledge of scientific publication regulations and best practices
  • Excellent communication skills, both written and verbal, with demonstrated success in creating and delivering effective presentations to senior-level audiences
  • Ability to build strong relationships with peers and cross functionally with partners outside of the team to enable higher performance, collaborative teamwork and leadership track record
  • Ability to form, maintain, and lead productive cross-functional working teams, including addressing issues that arise
  • Expert knowledge of relevant guidance including, but not limited to International Committee of Medical Journal Editors (ICMJE), Pharmaceutical Research and Manufacturers of America (PhRMA) guidelines, CME Open Payments reporting, Good Publication Practice (GPP4)
  • Certified Medical Publication Professional (CMPP) credentialed preferred
  • Microsoft Office and PowerPoint proficiency; Microsoft Project proficiency preferred
Industry:
  • Biotechnology
Employment Type:
  • Full-time
Equal Employment Opportunity:
At Biomea Fusion, we value bringing together individuals from diverse backgrounds to develop new and innovative solutions for patients. As an equal opportunity employer, we do not discriminate on the basis of race, color, religion, national origin, age, sex (including pregnancy), physical or mental disability, medical condition, genetic information gender identity or expression, sexual orientation, marital status, protected veteran status, or any other legally protected characteristics.
The anticipated salary range for this role is $155,000 to $175,000. An individual’s position within the range is influenced by multiple factors, including education, skills, years of relevant experience and geographical location. These factors will determine the salary offered. Base salary is one part of the overall total rewards program, which includes competitive cash compensation, including discretionary bonus program, equity awards and comprehensive benefits program.

Benefits Offered?

  • No

Bonus Offered?

  • No

Travel Required?

  • No

Location:

  • Redwood City, California - United States

Experience:

  • Mid-Senior level

Global Experience Needed?

  • No

Specialized Experience Needed?

  • No

Apply before:

  • Apr 14, 2024
Company Overview
Biomea Fusion
Biomea Fusion

Current Openings: 0

We are a biopharmaceutical company focused on the discovery and development of covalent small molecules to treat patients with genetically defined cancers and metabolic diseases. A covalent small molecule is a synthetic compound that forms a permanent bond to its target protein and offers a number of potential advantages over conventional non-covalent drugs including greater target selectivity, lower drug exposure and the ability to drive a deeper, more durable response. Leveraging our extensive expertise in covalent binding chemistry and development, we built our proprietary FUSION™ System platform to advance a pipeline of novel covalent therapies. Our lead product candidate, BMF-219, is an orally bioavailable, potent and selective covalent inhibitor of MENIN, an important transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers. Beyond BMF-219, we are utilizing our novel platform to develop covalent treatments against other high-value oncogenic drivers of cancer. Our goal is to utilize our capabilities and platform to become a leader in developing covalent small molecules in order to maximize the depth and durability of clinical benefit when treating various cancers. The name biomea derives from the Greek word bios, meaning “life,” and the Latin word mea, meaning “my.” At Biomea Fusion, we develop medicines to improve the life of the individual.
Are you an employee? 🌟
Explore Biotech Jobs

Find the one that suits your cosmic aspirations. Search open positions across the web, find opportunities uniquely matched to your skills, and read reviews on companies worldwide. 🚀💼🌎

Are you an employer? 🌟

Hire Top Talent in the Biotechnology Industry.

Post jobs, search for stellar candidates, and conduct the complete hiring process—all from your desktop or mobile phone. 🚀🔬👩‍🚀